Jiangsu Hengrui Medicine
PulseAugur coverage of Jiangsu Hengrui Medicine — every cluster mentioning Jiangsu Hengrui Medicine across labs, papers, and developer communities, ranked by signal.
- 2026-05-12 partnership Hengrui Medicine and Bristol Myers Squibb entered a global strategic collaboration to advance 13 early-stage drug projects. source
1 day(s) with sentiment data
-
Jiangsu Hengrui Medicine establishes new Zhejiang subsidiary with 50M RMB capital
Jiangsu Hengrui Medicine has established a new subsidiary in Zhejiang, named Zhejiang Hengrui Pharmaceutical Co., Ltd. The new company has a registered capital of 50 million RMB and will engage in activities such as med…
-
Investor boosts Pop Mart stake; FDA delays Hengrui drug; AI models GPT-5.6 and Claude mentioned
Investor Duan Yongping has increased his stake in Pop Mart, raising his shareholding to 7.65%. In other news, Hengrui Medicine received a complete response letter from the US FDA regarding its biologics license applicat…
-
Hong Kong approves tax relief; Hengrui Medicine advances drug trials
Hong Kong's Legislative Council has approved a bill to implement tax relief measures, including one-time tax reductions and increased deductions, which will be reflected in taxpayers' assessments for the 2025/26 and 202…
-
Hengrui Medicine subsidiaries get drug trial approvals; Xiangcai merger review resumes
Hengrui Medicine announced that its subsidiaries have received approval from China's National Medical Products Administration for clinical trials of three drugs. These include SHR-3821 for advanced solid tumors, Adebeli…
-
Innovent Biologics and Bristol Myers Squibb partner on 13 early-stage drug projects
Innovent Biologics has entered into a global strategic collaboration and licensing agreement with Bristol Myers Squibb to advance 13 early-stage projects across oncology, hematology, and immunology. This partnership aim…